Supercritical Fluid Chiral Separations - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Supercritical Fluid Chiral Separations
The combination of supercritical fluid chromatography with chiral separation media offers several analytival advantages over traditional liquid chromatography techniques.

Pharmaceutical Technology

By itself, supercritical fluid chromatography (SFC) is a well-known technique in pharmaceutical laboratories. Combined with chiral separation media, however, the technique can prove to be a powerful tool for reducing early-phase development costs and time. Although SFC chiral chromatography can be used at a process scale, its most typical application involves separating 50–100 g of materials for toxicology studies during the discovery and preclinical stages (see Figure 1).

Figure 1: Preparative separation using supercritical fluid chromatography.
Regis Technologies manufactures chiral stationary phases and performs SFC custom separation work using chiral stationary phases under good manufacturing practices (GMP).

"We work with a lot of companies that are just starting in their own process and looking for drugs to market," says Francis Mannerino, director of chromatography at Regis Technologies (Morton Grove, IL). "We see compounds in their earliest stage and a lot of them have difficulties in their purification. If they have a chiral separation built in, we try to marry the custom synthesis with the separation work or the purification work."

Better business, better science

Figure 2: Scientist using an SFC preparative instrument in the Regis Separations laboratory.
The method development for SFC chiral chromatography is similar to that for a typical liquid chromatography (LC) technique. SFC chiral chromatography uses the same columns that are used in LC and the same, readily available stationary phases (see Figure 2). Only the carrier is different. LC requires the use of 100% solvent, such as hexane–isopropyl alcohol (IPA) mobile phase. In SFC chiral chromatography, CO2 liquid is the main carrier with a 5–10% cosolvent added with it. Most cosolvents are hexane, IPA, methanol, and ethanol. About 95% of the separations by LC also can be separated with the SFC chiral method and, in some cases, the resolution can be improved over traditional LC results.

According to Mannerino, there are two main business advantages of SFC chiral chromatography: separations can be completed at least five times faster than separations using traditional LC and the technique uses about one-tenth of the amount of solvent, which reduces process costs and produces less hazardous waste.

"What it comes down to is speed. Getting your drug to toxicology testing faster. If you're going to fail, fail fast. Take your resources and put them into another project," says Mannerino.

The GMP road

As the first company performing SFC chiral separations under GMP, Regis faced several challenges. "For any new technique, qualifying for GMP is very trying,"says Mannerino. Fortunately, the company manufactures active pharmaceutical ingredients and finished-drug products under GMP conditions, so there were quality systems already in place. "We just needed to make the capability GMP, so it was about 40 or 50 new standard operating procedures, and we customized them for SFC equipment and personnel."

After about 10 months and several dry runs, the company gained GMP qualification. "Our challenge right now on the research side is improving productivity. There are no precedents, so we are developing different methods such as putting columns in series and using different phases in series," says Mannerino.

Increasing productivity is crucial for shortening cycle time. SFC separation is a continuous process. Once automated systems are developed and the technique is optimized, machines can run all day. "If you want a technique for commercial use, you have to optimize it as much as you can. That's the biggest challenge now:increasing productivity by doing the research," says Mannerino.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here